Dr. Sanchari Sinha Dutta

Feature Writer

B.Sc. Physiology, M.Sc. Physiology, Ph.D. Physiology

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world.

Since she was very young, Dr. Dutta was passionate about the world of science and making it accessible to all. During her time at school, Dr. Dutta particularly enjoyed taking part in biology experiments in the laboratory. The inner workings and diversity of the human body used to surprise her every day and eventually inspired her to become a biologist.

In order to learn more about the subject, Sanchari decided to take biology as her main subject at university and gained Bachelor of Science (B.Sc.) and Master of Science (M.Sc.) degrees in human physiology from the University of Calcutta, India.

This was followed by a Ph.D., also in physiology. During her tenure (2004 – 2010), she received the ‘Surg. Rear Admiral M.S. Malhotra Research Prize’ for best publication from the Defence Institute of Physiology and Allied Sciences, India.

Her thirst for knowledge and dream to be a science writer were always abreast throughout her academic tenure. However, instead of starting her career as a writer straight away, Sanchari decided to further her knowledge of the molecular biology of the human body and carried out postdoctoral research for 6 years after her Ph.D.

During this period, Dr. Dutta received ‘Dean of Faculty fellowship of Weizmann Institute of Science, Israel’ and ‘PBC fellowship for outstanding post-doctoral researchers from China and India in Israeli universities’.

Alongside bench work, she authored more than 10 original research articles, all published in renowned international journals.

In 2016, she started working with a leading medical communication company and formally became a freelance science writer. Since then, she has engaged in writing a wide variety of scientific articles, including original research articles, review articles, science discoveries, popular science articles, and healthcare articles. Her first review article as a science writer was recently published in the journal ‘Oxidative Medicine and Cellular Longevity’.

Her work with News Medical offers a great platform for a wide range of audience to learn about the science behind good health.

See less

Articles from Sanchari Sinha Dutta

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

A team of scientists from the United States has recently revealed how interactions between the SARS-CoV-2 nucleocapsid protein and the double-stranded RNA motifs impart distinct droplet properties that can support multiple viral functions. The study is currently available on the bioRxiv* preprint server.

16 Jun 2021

Could urine tests predict kidney injury and mortality in COVID-19?

A team of scientists from the Columbia University, New York, has recently identified a potential biomarker to predict acute kidney injury in COVID-19 patients. By analyzing urine samples of 444 COVID-19 patients, they have revealed that the urinary level of neutrophil gelatinase-associated lipocalin (NGAL) can be used to determine the severity and duration of acute kidney and tubular injuries, as well as to predict the risk of mortality in acute COVID-19 patients.

15 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

Antihistamines might be effective in long-COVID

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.

8 Jun 2021

No point vaccinating those who’ve had COVID-19: Cleveland Clinic study suggests

The study findings reveal that individuals with previous SARS-CoV-2 infection do not get additional benefits from vaccination, indicating that COVID-19 vaccines should be prioritized to individuals without prior infection. The study is currently available on the medRxiv* preprint server.

8 Jun 2021

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server.

8 Jun 2021

Researchers uncover molecular mechanism linking Parkinson’s disease with COVID-19

The study findings reveal that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection results in abnormal modification of some lung proteins, which are subsequently transported to the brain via exosomes. In the brain, these modified lung proteins disrupt the normal functioning of proteins that are related to Parkinson’s disease.

7 Jun 2021

Accuracy of three COVID-sniffing dogs exceeds 85%

A team of scientists from Italy and Brazil has recently conducted a training program for sniffer dogs to detect coronavirus disease 2019 (COVID-19). They have trained the dogs to accurately sense COVID-19 specific volatile organic compounds in sweat samples collected from COVID-19 patients. The study is currently available on the medRxiv* preprint server.

7 Jun 2021

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

A recent study conducted by a team of scientists in the Netherlands has revealed that while severely affected hospitalized COVID-19 patients and vaccinated individuals are capable of neutralizing the B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2, a significant proportion of non-hospitalized patients with less severe COVID-19 remain susceptible to these viral variants.

2 Jun 2021